Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$26.55
+1.5%
$33.94
$17.52
$43.81
$714.73M2.6452,463 shs275,687 shs
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$6.96
+1.5%
$6.25
$3.33
$7.05
$1.32B1.321.84 million shs1.84 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$3.80
-1.8%
$6.73
$1.63
$8.83
$432.52M1.662.78 million shs2.73 million shs
Sharecare, Inc. stock logo
SHCR
Sharecare
$0.81
+9.5%
$0.85
$0.48
$1.80
$290.44M0.261.62 million shs1.55 million shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-3.00%-0.57%-18.55%-17.50%-1.80%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
+1.70%+5.29%+6.60%+20.86%+63.06%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-10.00%-23.21%-43.59%-15.13%-33.51%
Sharecare, Inc. stock logo
SHCR
Sharecare
-3.76%+17.23%-14.12%-30.55%-51.75%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
2.4899 of 5 stars
3.52.00.00.02.13.30.6
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.444 of 5 stars
1.31.00.04.93.31.70.6
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.1886 of 5 stars
4.01.00.04.71.82.50.6
Sharecare, Inc. stock logo
SHCR
Sharecare
0.9869 of 5 stars
2.02.00.00.02.31.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.00
Buy$61.33131.01% Upside
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.50
Moderate Buy$7.507.76% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.08
Hold$6.7377.03% Upside
Sharecare, Inc. stock logo
SHCR
Sharecare
2.00
Hold$1.0023.46% Upside

Current Analyst Ratings

Latest BKD, FATE, ARCT, and SHCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$7.00
4/15/2024
Sharecare, Inc. stock logo
SHCR
Sharecare
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
4/11/2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/9/2024
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
4/1/2024
Sharecare, Inc. stock logo
SHCR
Sharecare
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
3/28/2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$2.00 ➝ $6.00
3/20/2024
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
3/19/2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$7.00
3/8/2024
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/27/2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $7.00
2/27/2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$6.00 ➝ $10.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$169.93M4.21N/AN/A$10.42 per share2.55
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$3.02B0.44$0.88 per share7.91$2.15 per share3.24
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$63.53M6.81N/AN/A$3.74 per share1.02
Sharecare, Inc. stock logo
SHCR
Sharecare
$445.25M0.65N/AN/A$1.22 per share0.66

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$29.73M-$1.04N/A10.06N/A-15.65%-18.22%-11.95%5/8/2024 (Confirmed)
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/7/2024 (Confirmed)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$160.93M-$1.64N/AN/AN/A-253.30%-38.17%-28.42%5/1/2024 (Estimated)
Sharecare, Inc. stock logo
SHCR
Sharecare
-$128.50M-$0.37N/AN/AN/A-28.86%-17.11%-12.33%5/9/2024 (Confirmed)

Latest BKD, FATE, ARCT, and SHCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Sharecare, Inc. stock logo
SHCR
Sharecare
-$0.04N/A+$0.04N/AN/AN/A  
5/8/2024N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.17N/A+$1.17N/AN/AN/A  
5/7/2024N/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.17N/A+$0.17N/AN/AN/A  
3/28/2024Q4 2023
Sharecare, Inc. stock logo
SHCR
Sharecare
-$0.04-$0.06-$0.02-$0.02$113.88 million$105.28 million
3/7/2024Q4 2023
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million
2/26/202412/31/2023
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.57-$0.45+$0.12-$0.45$0.85 million$1.68 million    
2/20/2024Q4 2023
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.19-$0.40-$0.21-$0.40N/A$754.48 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Sharecare, Inc. stock logo
SHCR
Sharecare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
4.72
4.72
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
9.40
0.80
0.80
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.48
8.48
Sharecare, Inc. stock logo
SHCR
Sharecare
N/A
2.30
2.30

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Sharecare, Inc. stock logo
SHCR
Sharecare
35.08%

Insider Ownership

CompanyInsider Ownership
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
13.80%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
1.50%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5.04%
Sharecare, Inc. stock logo
SHCR
Sharecare
29.27%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18026.92 million23.20 millionOptionable
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
25,200189.34 million186.50 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
181113.82 million108.08 millionOptionable
Sharecare, Inc. stock logo
SHCR
Sharecare
3,352358.57 million253.62 millionOptionable

BKD, FATE, ARCT, and SHCR Headlines

SourceHeadline
Investors who lost money on Sharecare, Inc. (SHCR) should contact Levi & Korsinsky about pending Class Action - SHCRInvestors who lost money on Sharecare, Inc. (SHCR) should contact Levi & Korsinsky about pending Class Action - SHCR
markets.businessinsider.com - April 26 at 8:33 PM
Shareholders that Lost Money on Sharecare, Inc.(SHCR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreShareholders that Lost Money on Sharecare, Inc.(SHCR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
accesswire.com - April 26 at 2:20 PM
Sharecare, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 18, 2024 to Discuss Your Rights – SHCRSharecare, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 18, 2024 to Discuss Your Rights – SHCR
accesswire.com - April 26 at 2:15 PM
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the FirmDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the Firm
accesswire.com - April 26 at 1:30 PM
ROSEN, A LEADING NATIONAL FIRM, Encourages Sharecare, Inc. Investors to Secure Counsel Before ...ROSEN, A LEADING NATIONAL FIRM, Encourages Sharecare, Inc. Investors to Secure Counsel Before ...
bakersfield.com - April 26 at 10:31 AM
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SharecareSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sharecare
markets.businessinsider.com - April 26 at 5:30 AM
Shareholders of Sharecare, Inc. Should Contact Levi & Korsinsky Before June 18, 2024 to Discuss Your Rights - SHCRShareholders of Sharecare, Inc. Should Contact Levi & Korsinsky Before June 18, 2024 to Discuss Your Rights - SHCR
accesswire.com - April 26 at 12:10 AM
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the FirmSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the Firm
prnewswire.com - April 25 at 11:30 PM
Sharecare, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SHCRSharecare, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SHCR
accesswire.com - April 25 at 9:00 PM
Shareholders of Sharecare, Inc. Should Contact Levi & Korsinsky LLP Before June 18, 2024 to Discuss Your Rights – SHCRShareholders of Sharecare, Inc. Should Contact Levi & Korsinsky LLP Before June 18, 2024 to Discuss Your Rights – SHCR
msn.com - April 25 at 7:29 PM
SHCR LAWSUIT ALERT: Levi & Korsinsky Notifies Sharecare, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSHCR LAWSUIT ALERT: Levi & Korsinsky Notifies Sharecare, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
accesswire.com - April 25 at 4:00 PM
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the FirmDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the Firm
accesswire.com - April 25 at 1:15 PM
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the FirmDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Sharecare, Inc. with Losses to Contact the Firm
accesswire.com - April 24 at 6:45 PM
SHCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sharecare Inc. Investors Can Join the Class Action Lawsuit!SHCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sharecare Inc. Investors Can Join the Class Action Lawsuit!
stockhouse.com - April 24 at 6:25 PM
Private Management Group Inc. Takes Position in Sharecare, Inc. (NASDAQ:SHCR)Private Management Group Inc. Takes Position in Sharecare, Inc. (NASDAQ:SHCR)
marketbeat.com - April 24 at 4:27 PM
Sharecare awarded three-year NCQA Accreditation for Case ManagementSharecare awarded three-year NCQA Accreditation for Case Management
globenewswire.com - April 24 at 9:00 AM
Sharecare to report first quarter fiscal 2024 financial results on Thursday, May 9Sharecare to report first quarter fiscal 2024 financial results on Thursday, May 9
finance.yahoo.com - April 24 at 7:40 AM
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Sharecare Inc. to Contact Law FirmINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Sharecare Inc. to Contact Law Firm
prnewswire.com - April 23 at 5:16 PM
ATTENTION NASDAQ: SHCR INVESTORS: Contact Berger Montague About a Sharecare Class Action LawsuitATTENTION NASDAQ: SHCR INVESTORS: Contact Berger Montague About a Sharecare Class Action Lawsuit
bakersfield.com - April 23 at 4:37 PM
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SharecareINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sharecare
markets.businessinsider.com - April 23 at 4:37 PM
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sharecare, Inc. (SHCR) InvestorsThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sharecare, Inc. (SHCR) Investors
businesswire.com - April 23 at 12:06 PM
SHCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sharecare Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!SHCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sharecare Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
prnewswire.com - April 22 at 10:26 PM
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Sharecare, Inc. (SHCR) InvestorsGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Sharecare, Inc. (SHCR) Investors
businesswire.com - April 22 at 5:10 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sharecare, Inc. - SHCRSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sharecare, Inc. - SHCR
prnewswire.com - April 22 at 5:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arcturus Therapeutics logo

Arcturus Therapeutics

NASDAQ:ARCT
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Brookdale Senior Living logo

Brookdale Senior Living

NYSE:BKD
Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.
Fate Therapeutics logo

Fate Therapeutics

NASDAQ:FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Sharecare logo

Sharecare

NASDAQ:SHCR
Sharecare, Inc. operates as a digital healthcare platform company. Its Sharecare platform connects people, patients, providers, employers, health plans, government organizations, and communities that optimize individual and population-wide well-being. The company offers enterprise solutions based on a software-as-a-service model that allows enterprise clients to message, motivate, and manage their populations, as well as measure their population progress; a suite of data and information-driven solutions; and life sciences solutions, which provides members with personalized information, programs, and resources to enhance their health and well-being. It also operates RealAge, a platform for health assessment to assess behaviors and existing conditions of its members and provide metric for their physical health. In addition, the company provides secure, automated release of information, audit, and business consulting services to streamline the medical records process for medical facilities. It sells its solutions through direct sales organization and partner relationships. The company was founded in 2009 and is headquartered in Atlanta, Georgia.